Genmab — Oktober 2016
-
AL er da en ret stor indikation - In the United States, AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from ages 50-80, although there are a few cases of people being diagnosed as early as their late 20s. About two-thirds of the patients are male.
-
Tak Budweiss. deter en opfølgning på en historie, vi havde oppe at vende i august. http://www.jwatch.org/na42154/2016/08/28/daratumumab-advanced-light-chain-amyloidosis
-
Though primary systemic amyloidosis is very rare disease but it has spread across the world. According to article published by American Society of Nephrology (ASN), it is estimated that around five to twelve people per million per year are affected by primary systemic amyloidosis
-
Et andet studie med 18 pts har vi også tidligere haft oppe: http://www.onclive.com/web-exclusives/daratumumab-produces-dramatic-responses-in-relapsed-light-chain-amyloidosis
-
-
Fantastisk ...Tak for link alle.
-
Alelau...Der er ingen grund til, at bekymre sig så meget kursen lige nu. Udlandet sælger ud og holder sig væk fra danske aktier - også pharma. Det vigtigste er, at casen hele tiden underbygges. Det er den jeg har fokus på.
-
er de ikke bedre bare at malke koen de næste mange år??
-
det
-
Enig Solsen.
-
God morgen
-
-
Mine tanker går uvist af årsagerne denne morgen på en analytiker fra HSBC.
-
Hvad mener du med det?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind